Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERiT: DCS and Mifepristone for Social Anxiety
NCT02099825Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2014
- Primary completion
- Oct 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of d-cycloserine and mifepristone in Social Anxiety Disorder (SAD), sponsored by Washington University School of Medicine. Primary endpoint: Medication tolerability and safety. Started Jan 2014; status: terminated.
02
Drugs
d-cycloserinemifepristone
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT02099825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099825.